Menendez Clara, Alonso Pedro
Barcelona Center for International Health Research (CRESIB), Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Spain.
Hum Vaccin. 2010 Jan;6(1):21-6. doi: 10.4161/hv.6.1.10331. Epub 2010 Jan 15.
Malaria during pregnancy continues to be an important cause of maternal and infant morbidity and mortality in endemic areas, where at least 50 million pregnancies are exposed to the infection every year. Important progress has been made in the last years especially in sub-Saharan Africa, with the introduction of strategies to prevent malaria in pregnancy consisting of intermittent preventive treatment and insecticide treated nets. However, their coverage is still unacceptably low and malaria continues to demand a huge toll on pregnant women and their newborns. Thus, there is a need to explore other preventive strategies such as a vaccine against malaria, which combined with the current tools would maximize the protection efficacy. Given the specific and complex characteristics of the pregnancy status, it is important to review all the issues that would need to be considered in the evaluation of a vaccine against malaria in pregnancy while waiting for it to become available.
在疟疾流行地区，孕期疟疾仍然是导致孕产妇和婴儿发病及死亡的重要原因，每年至少有5000万例妊娠面临感染风险。过去几年已取得重要进展，特别是在撒哈拉以南非洲地区，通过采用包括间歇性预防治疗和长效驱虫蚊帐在内的孕期疟疾预防策略。然而，这些措施的覆盖率仍然低得令人无法接受，疟疾继续给孕妇及其新生儿带来巨大损失。因此，有必要探索其他预防策略，如疟疾疫苗，它与现有工具相结合可使预防效果最大化。鉴于孕期的特殊和复杂特征，在等待疟疾疫苗上市的同时，审查评估孕期疟疾疫苗时需要考虑的所有问题非常重要。
